TME Pharma NV (XPAR:ALTME) Pretax Margin %: 4,381.48% (As of Dec. 2025)


What is TME Pharma NV Pretax Margin %?

TME Pharma NV XPAR:ALTME -3.45% Pretax Margin % is 4,381.48% as of Dec. 2025. The stock has 4 warning signs investors should review. Among 939 Biotechnology companies, TME Pharma NV ranks worse than 106496.17% on this metric.

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. TME Pharma NV's Pre-Tax Income for the six months ended in Dec. 2025 was €-1.18 Mil. TME Pharma NV's Revenue for the six months ended in Dec. 2025 was €-0.03 Mil. Therefore, TME Pharma NV's pretax margin for the quarter that ended in Dec. 2025 was 4,381.48%.

The historical rank and industry rank for TME Pharma NV's Pretax Margin % or its related term are showing as below:


XPAR:ALTME's Pretax Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -89.42
* Ranked among companies with meaningful Pretax Margin % only.

TME Pharma NV  (XPAR:ALTME) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.

TME Pharma NV Pretax Margin % Related Terms

TME Pharma NV Pretax Margin % Historical Data

* Premium members only.

The historical data trend for TME Pharma NV's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TME Pharma NV Pretax Margin % Chart

TME Pharma NV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Pretax Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

TME Pharma NV Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 -7,785.19 4,381.48

XPAR:ALTME vs VRTX, REGN, ALNY: Pretax Margin % Comparison

For the Biotechnology subindustry, TME Pharma NV's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TME Pharma NV Pretax Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TME Pharma NV's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where TME Pharma NV's Pretax Margin % falls into.


TME Pharma NV Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

TME Pharma NV's Pretax Margin for the fiscal year that ended in Dec. 2025 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-3.285/0
= %

TME Pharma NV's Pretax Margin for the quarter that ended in Dec. 2025 is calculated as

Pretax Margin=Pre-Tax Income (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-1.183/-0.027
=4,381.48 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Pretax Margin % →
What does a Pretax Margin % of 4,381.48% mean?
TME Pharma NV (XPAR:ALTME) has a Pretax Margin % of 4,381.48% as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on TME Pharma NV and its competitors. According to the industry distribution chart, TME Pharma NV ranks #999999 out of 939 companies in the Biotechnology industry.
Is TME Pharma NV's Pretax Margin % too high?
TME Pharma NV's current Pretax Margin % is 4,381.48%. Based on the distribution chart, TME Pharma NV ranks #999999 out of 939 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does TME Pharma NV's Pretax Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, TME Pharma NV ranks #999999 out of 939 companies for Pretax Margin %. This places TME Pharma NV in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on TME Pharma NV and its competitors. TME Pharma NV's current Pretax Margin % is 4,381.48%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TME Pharma NV stock overvalued right now?
TME Pharma NV (XPAR:ALTME) has a current Pretax Margin % of 4,381.48%. The current Pretax Margin % is 4,381.48%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For TME Pharma NV (XPAR:ALTME), the current Pretax Margin % is 4,381.48% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TME Pharma NV Business Description

Other Exchanges 0N6A:Germany
Address Max-Dohrn-Strasse 8-10, Berlin, DEU, 10589
TME Pharma NV is a clinical-stage biopharmaceutical company focused on developing novel therapies for treatment of the aggressive cancers and specializing in approaches targeting the tumor microenvironment. Its enhances the effectiveness of cancer treatments including current standards of care (such as antivascular agents, chemotherapy and radiotherapy) and immune-oncology approaches (such as immune checkpoint inhibitors). The company's Spiegelmer platform has generated a proprietary pipeline of clinical-stage product candidates including its cancer drug candidate NOX-A12 and its second clinical-stage asset, NOX-E36, now planned to be developed in eye diseases. The company has one segment active in pioneering the development of a new class of proprietary therapeutics called Spiegelmers.